Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2021;1311:161–172. doi: 10.1007/978-3-030-65768-0_12

Cancer Stem Cell Metabolism.

Fidelia B Alvina, Arvin M Gouw, Anne Le
PMCID: PMC9703852  PMID: 34014542

Abstract

Cancer stem cells (CSCs), also known as tumorinitiating cells (TICs), are a group of cells found within cancer cells. Like normal stem cells, CSCs can proliferate, engage in self-renewal, and are often implicated in the recurrence of tumors after therapy [1, 2]. The existence of CSCs in various types of cancer has been proven, such as in acute myeloid leukemia (AML) [3], breast [4], pancreatic [5], and lung cancers [6], to name a few. There are two theories regarding the origin of CSCs. First, CSCs may have arisen from normal stem/progenitor cells that experienced changes in their environment or genetic mutations. On the other hand, CSCs may also have originated from differentiated cells that underwent genetic and/or heterotypic modifications [7]. Either way, CSCs reprogram their metabolism in order to support tumorigenesis.

Full text of this article can be found in Bookshelf.

References

  1. Dick, J. E. (2008). Stem cell concepts renew cancer research. Blood, 112(13), 4793–4807. doi: 10.1182/blood-2008-08-077941. [DOI] [PubMed]
  2. Reya, T., et al. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414(6859), 105–111. doi: 10.1038/35102167. [DOI] [PubMed]
  3. Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), 730–737. doi: 10.1038/nm0797-730. [DOI] [PubMed]
  4. Crabtree, J. S., & Miele, L. (2018). Breast cancer stem cells. Biomedicine, 6, 3. doi: 10.3390/biomedicines6030077. [DOI] [PMC free article] [PubMed]
  5. Hermann, P. C., et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1(3), 313–323. doi: 10.1016/j.stem.2007.06.002. [DOI] [PubMed]
  6. Ho, M. M., et al. (2007). Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Research, 67(10), 4827–4833. doi: 10.1158/0008-5472.CAN-06-3557. [DOI] [PubMed]
  7. Yu, Z., et al. (2012). Cancer stem cells. The International Journal of Biochemistry & Cell Biology, 44(12), 2144–2151. doi: 10.1016/j.biocel.2012.08.022. [DOI] [PMC free article] [PubMed]
  8. Sancho, P., Barneda, D., & Heeschen, C. (2016). Hallmarks of cancer stem cell metabolism. British Journal of Cancer, 114(12), 1305–1312. doi: 10.1038/bjc.2016.152. [DOI] [PMC free article] [PubMed]
  9. Bose, S., Zhang, C., & Le, A. (2021). Glucose metabolism in cancer: The Warburg effect and beyond. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_1 doi: 10.1007/978-3-030-65768-0_1. [DOI] [PMC free article] [PubMed]
  10. Aguilar, E., et al. (2016). Metabolic reprogramming and dependencies associated with epithelial cancer stem cells independent of the epithelial-mesenchymal transition program. Stem Cells, 34(5), 1163–1176. doi: 10.1002/stem.2286. [DOI] [PMC free article] [PubMed]
  11. Song, K., et al. (2015). Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: Regulation by MIR-122. Oncotarget, 6(38), 40822–40835. doi: 10.18632/oncotarget.5812. [DOI] [PMC free article] [PubMed]
  12. Shen, Y. A., et al. (2015). Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma. Cell Cycle, 14(1), 86–98. doi: 10.4161/15384101.2014.974419. [DOI] [PMC free article] [PubMed]
  13. Shibuya, K., et al. (2015). Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. Oncotarget, 6(2), 651–661. doi: 10.18632/oncotarget.2892. [DOI] [PMC free article] [PubMed]
  14. Ciavardelli, D., et al. (2014). Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment. Cell Death & Disease, 5, e1336. doi: 10.1038/cddis.2014.285. [DOI] [PMC free article] [PubMed]
  15. Xie, H., et al. (2014). Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metabolism, 19(5), 795–809. doi: 10.1016/j.cmet.2014.03.003. [DOI] [PMC free article] [PubMed]
  16. Le, A., et al. (2010). Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 107(5), 2037–2042. doi: 10.1073/pnas.0914433107. [DOI] [PMC free article] [PubMed]
  17. Rajeshkumar, N. V., et al. (2015). Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function. Cancer Research, 75(16), 3355–3364. doi: 10.1158/0008-5472.CAN-15-0108. [DOI] [PMC free article] [PubMed]
  18. Dutta, P., et al. (2013). Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors. Cancer Research, 73(14), 4190–4195. doi: 10.1158/0008-5472.CAN-13-0465. [DOI] [PMC free article] [PubMed]
  19. Li, T., Copeland, C., & Le, A. (2021). Glutamine metabolism in cancer. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_2 doi: 10.1007/978-3-030-65768-0_2. [DOI] [PMC free article] [PubMed]
  20. Le, A., et al. (2012). Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metabolism, 15(1), 110–121. doi: 10.1016/j.cmet.2011.12.009. [DOI] [PMC free article] [PubMed]
  21. Kim, J. H., et al. (2018). Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism. Scientific Reports, 8(1), 409. doi: 10.1038/s41598-017-18762-4. [DOI] [PMC free article] [PubMed]
  22. Zimmermann, S. C., et al. (2016). Allosteric glutaminase inhibitors based on a 1,4-di(5-amino-1,3,4-thiadiazol-2-yl)butane scaffold. ACS Medicinal Chemistry Letters, 7(5), 520–524. doi: 10.1021/acsmedchemlett.6b00060. [DOI] [PMC free article] [PubMed]
  23. Rais, R., et al. (2016). Discovery of 6-diazo-5-oxo-l-norleucine (DON) prodrugs with enhanced CSF delivery in monkeys: a potential treatment for glioblastoma. Journal of Medicinal Chemistry, 59(18), 8621–8633. doi: 10.1021/acs.jmedchem.6b01069. [DOI] [PubMed]
  24. Xiang, Y., et al. (2015). Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. The Journal of Clinical Investigation, 125(6), 2293–2306. doi: 10.1172/JCI75836. [DOI] [PMC free article] [PubMed]
  25. Dang, C. V., et al. (2011). Therapeutic targeting of cancer cell metabolism. Journal of Molecular Medicine (Berlin), 89(3), 205–212. doi: 10.1007/s00109-011-0730-x. [DOI] [PMC free article] [PubMed]
  26. Hirschey, M. D., et al. (2015). Dysregulated metabolism contributes to oncogenesis. Seminars in Cancer Biology, 35(Suppl), S129–S150. doi: 10.1016/j.semcancer.2015.10.002. [DOI] [PMC free article] [PubMed]
  27. Elgogary, A., et al. (2016). Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 113(36), E5328–E5336. doi: 10.1073/pnas.1611406113. [DOI] [PMC free article] [PubMed]
  28. Udupa, S., et al. (2019). Upregulation of the glutaminase II pathway contributes to glutamate production upon glutaminase 1 inhibition in pancreatic cancer. Proteomics, 19(21–22), e1800451. doi: 10.1002/pmic.201800451. [DOI] [PMC free article] [PubMed]
  29. Nguyen, T., et al. (2019). Uncovering the role of N-acetyl-aspartyl-glutamate as a glutamate reservoir in cancer. Cell Reports, 27(2), 491–501. e6. doi: 10.1016/j.celrep.2019.03.036. [DOI] [PMC free article] [PubMed]
  30. Li, D., et al. (2015). Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy. Oncotarget, 6(31), 31151–31163. doi: 10.18632/oncotarget.5150. [DOI] [PMC free article] [PubMed]
  31. Cuyas, E., et al. (2018). Mitostemness. Cell Cycle, 17(8), 918–926. doi: 10.1080/15384101.2018.1467679. [DOI] [PMC free article] [PubMed]
  32. Liu, P. P., et al. (2014). Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death and Differentiation, 21(1), 124–135. doi: 10.1038/cdd.2013.131. [DOI] [PMC free article] [PubMed]
  33. Peiris-Pages, M., et al. (2016). Cancer stem cell metabolism. Breast Cancer Research, 18(1), 55. doi: 10.1186/s13058-016-0712-6. [DOI] [PMC free article] [PubMed]
  34. Lonardo, E., et al. (2013). Metformin targets the metabolic Achilles heel of human pancreatic cancer stem cells. PLoS One, 8(10), e76518. doi: 10.1371/journal.pone.0076518. [DOI] [PMC free article] [PubMed]
  35. Sancho, P., et al. (2015). MYC/PGC-1alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metabolism, 22(4), 590–605. doi: 10.1016/j.cmet.2015.08.015. [DOI] [PubMed]
  36. Reid, M. A., Dai, Z., & Locasale, J. W. (2017). The impact of cellular metabolism on chromatin dynamics and epigenetics. Nature Cell Biology, 19(11), 1298–1306. doi: 10.1038/ncb3629. [DOI] [PMC free article] [PubMed]
  37. Wainwright, E. N., & Scaffidi, P. (2017). Epigenetics and cancer stem cells: Unleashing, hijacking, and restricting cellular plasticity. Trends Cancer, 3(5), 372–386. doi: 10.1016/j.trecan.2017.04.004. [DOI] [PMC free article] [PubMed]
  38. Mitani, M., et al. (1976). Salinomycin effects on mitochondrial ion translocation and respiration. Antimicrobial Agents and Chemotherapy, 9(4), 655–660. doi: 10.1128/aac.9.4.655. [DOI] [PMC free article] [PubMed]
  39. Gupta, P. B., et al. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 138(4), 645–659. doi: 10.1016/j.cell.2009.06.034. [DOI] [PMC free article] [PubMed]
  40. Zhi, Q. M., et al. (2011). Salinomycin can effectively kill ALDH (high) stem-like cells on gastric cancer. Biomedicine & Pharmacotherapy, 65(7), 509–515. doi: 10.1016/j.biopha.2011.06.006. [DOI] [PubMed]
  41. Zhang, G. N., et al. (2011). Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Letters, 313(2), 137–144. doi: 10.1016/j.canlet.2011.05.030. [DOI] [PubMed]
  42. Lyakhovich, A., & Lleonart, M. E. (2016). Bypassing mechanisms of mitochondria-mediated cancer stem cells resistance to chemo- and radiotherapy. Oxidative Medicine and Cellular Longevity, 2016, 1716341. doi: 10.1155/2016/1716341. [DOI] [PMC free article] [PubMed]
  43. Garcia-Heredia, J. M., & Carnero, A. (2015). Decoding Warburg’s hypothesis: Tumor-related mutations in the mitochondrial respiratory chain. Oncotarget, 6(39), 41582–41599. doi: 10.18632/oncotarget.6057. [DOI] [PMC free article] [PubMed]
  44. Hirsch, H. A., et al. (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Research, 69(19), 7507–7511. doi: 10.1158/0008-5472.CAN-09-2994. [DOI] [PMC free article] [PubMed]
  45. Dattilo, R., et al. (2020). Pyrvinium pamoate induces death of triple-negative breast cancer stem-like cells and reduces metastases through effects on lipid anabolism. Cancer Research, 80(19), 4087–4102. doi: 10.1158/0008-5472.CAN-19-1184. [DOI] [PMC free article] [PubMed]
  46. Fiorillo, M., et al. (2016). Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget, 7(23), 34084–34099. doi: 10.18632/oncotarget.9122. [DOI] [PMC free article] [PubMed]
  47. Fiorillo, M., et al. (2016). Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging (Albany NY), 8(8), 1593–1607. doi: 10.18632/aging.100983. [DOI] [PMC free article] [PubMed]
  48. Sosa, V., et al. (2013). Oxidative stress and cancer: An overview. Ageing Research Reviews, 12(1), 376–390. doi: 10.1016/j.arr.2012.10.004. [DOI] [PubMed]
  49. Redza-Dutordoir, M., & Averill-Bates, D. A. (2016). Activation of apoptosis signalling pathways by reactive oxygen species. Biochimica et Biophysica Acta, 1863(12), 2977–2992. doi: 10.1016/j.bbamcr.2016.09.012. [DOI] [PubMed]
  50. Fan, P. C., et al. (2019). Quantitative proteomics reveals mitochondrial respiratory chain as a dominant target for carbon ion radiation: Delayed reactive oxygen species generation caused DNA damage. Free Radical Biology & Medicine, 130, 436–445. doi: 10.1016/j.freeradbiomed.2018.10.449. [DOI] [PubMed]
  51. Yang, H., et al. (2018). The role of cellular reactive oxygen species in cancer chemotherapy. Journal of Experimental & Clinical Cancer Research, 37(1), 266. doi: 10.1186/s13046-018-0909-x. [DOI] [PMC free article] [PubMed]
  52. Piao, L. S., et al. (2012). CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Letters, 315(2), 129–137. doi: 10.1016/j.canlet.2011.10.012. [DOI] [PubMed]
  53. Gomez-Casal, R., et al. (2013). Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Molecular Cancer, 12(1), 94. doi: 10.1186/1476-4598-12-94. [DOI] [PMC free article] [PubMed]
  54. Collins, A. T., et al. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research, 65(23), 10946–10951. doi: 10.1158/0008-5472.CAN-05-2018. [DOI] [PubMed]
  55. Al-Hajj, M., et al. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100(7), 3983–3988. doi: 10.1073/pnas.0530291100. [DOI] [PMC free article] [PubMed]
  56. Dalerba, P., et al. (2007). Phenotypic characterization of human colorectal cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America, 104(24), 10158–10163. doi: 10.1073/pnas.0703478104. [DOI] [PMC free article] [PubMed]
  57. Ishimoto, T., et al. (2011). CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell, 19(3), 387–400. doi: 10.1016/j.ccr.2011.01.038. [DOI] [PubMed]
  58. Diehn, M., et al. (2009). Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 458(7239), 780–783. doi: 10.1038/nature07733. [DOI] [PMC free article] [PubMed]
  59. Schulz, A., et al. (2019). Cancer stem cells and radioresistance: DNA repair and beyond. Cancers (Basel), 11, 6. doi: 10.3390/cancers11060862. [DOI] [PMC free article] [PubMed]
  60. Park, J. K., et al. (2021). The heterogeneity of lipid metabolism in cancer. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_3 doi: 10.1007/978-3-030-65768-0_3. [DOI] [PMC free article] [PubMed]
  61. Sun, M., & Yang, Z. (2019). Metabolomic studies of live single cancer stem cells using mass spectrometry. Analytical Chemistry, 91(3), 2384–2391. doi: 10.1021/acs.analchem.8b05166. [DOI] [PMC free article] [PubMed]
  62. Gouw, A. M., et al. (2019). The MYC oncogene cooperates with sterol-regulated element-binding protein to regulate lipogenesis essential for neoplastic growth. Cell Metabolism, 30(3), 556–572. e5. doi: 10.1016/j.cmet.2019.07.012. [DOI] [PMC free article] [PubMed]
  63. Foster, D. W. (2012). Malonyl-CoA: The regulator of fatty acid synthesis and oxidation. The Journal of Clinical Investigation, 122(6), 1958–1959. doi: 10.1172/JCI63967. [DOI] [PMC free article] [PubMed]
  64. Begicevic, R. R., Arfuso, F., & Falasca, M. (2019). Bioactive lipids in cancer stem cells. World Journal of Stem Cells, 11(9), 693–704. doi: 10.4252/wjsc.v11.i9.693. [DOI] [PMC free article] [PubMed]
  65. Dang, C. V., Le, A., & Gao, P. (2009). MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clinical Cancer Research, 15(21), 6479–6483. doi: 10.1158/1078-0432.CCR-09-0889. [DOI] [PMC free article] [PubMed]
  66. Le, A., & Dang, C. V. (2013). Studying Myc’s role in metabolism regulation. Methods in Molecular Biology, 1012, 213–219. doi: 10.1007/978-1-62703-429-6_14. [DOI] [PMC free article] [PubMed]
  67. Hanai, J. I., et al. (2013). ATP citrate lyase knockdown impacts cancer stem cells in vitro. Cell Death & Disease, 4, e696. doi: 10.1038/cddis.2013.215. [DOI] [PMC free article] [PubMed]
  68. Rios Garcia, M., et al. (2017). Acetyl-CoA carboxylase 1-dependent protein acetylation controls breast cancer metastasis and recurrence. Cell Metabolism, 26(6), 842–855. e5. doi: 10.1016/j.cmet.2017.09.018. [DOI] [PubMed]
  69. Corominas-Faja, B., et al. (2014). Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. Oncotarget, 5(18), 8306–8316. doi: 10.18632/oncotarget.2059. [DOI] [PMC free article] [PubMed]
  70. Yasumoto, Y., et al. (2016). Inhibition of fatty acid synthase decreases expression of stemness markers in glioma stem cells. PLoS One, 11(1), e0147717. doi: 10.1371/journal.pone.0147717. [DOI] [PMC free article] [PubMed]
  71. Tracz-Gaszewska, Z., & Dobrzyn, P. (2019). Stearoyl-CoA desaturase 1 as a therapeutic target for the treatment of cancer. Cancers (Basel), 11, 7. doi: 10.3390/cancers11070948. [DOI] [PMC free article] [PubMed]
  72. Gruenbacher, G., & Thurnher, M. (2018). Mevalonate metabolism in cancer stemness and trained immunity. Frontiers in Oncology, 8, 394. doi: 10.3389/fonc.2018.00394. [DOI] [PMC free article] [PubMed]
  73. Chen, C. L., et al. (2016). NANOG metabolically reprograms tumor-initiating stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism. Cell Metabolism, 23(1), 206–219. doi: 10.1016/j.cmet.2015.12.004. [DOI] [PMC free article] [PubMed]
  74. Kuo, C. Y., & Ann, D. K. (2018). When fats commit crimes: Fatty acid metabolism, cancer stemness and therapeutic resistance. Cancer Communications (Lond), 38(1), 47. doi: 10.1186/s40880-018-0317-9. [DOI] [PMC free article] [PubMed]
  75. Hoang, G., Udupa, S., & Le, A. (2019). Application of metabolomics technologies toward cancer prognosis and therapy. International Review of Cell and Molecular Biology, 347, 191–223. doi: 10.1016/bs.ircmb.2019.07.003. [DOI] [PubMed]

RESOURCES